The molecular processes that determine the outcome of influenza virus infection in humans are multifactorial and involve a complex interplay between host, viral and bacterial factors 1 . However, it is generally accepted that a strong innate immune dysregulation known as 'cytokine storm' contributes to the pathology of infections with the 1918 H1N1 pandemic or the highly pathogenic avian influenza viruses of the H5N1 subtype 2-4 . The RNA sensor retinoic acid-inducible gene I (RIG-I) plays an important role in sensing viral infection and initiating a signalling cascade that leads to interferon expression 5 . Here, we show that short aberrant RNAs (mini viral RNAs (mvRNAs)), produced by the viral RNA polymerase during the replication of the viral RNA genome, bind to and activate RIG-I and lead to the expression of interferon-β . We find that erroneous polymerase activity, dysregulation of viral RNA replication or the presence of avian-specific amino acids underlie mvRNA generation and cytokine expression in mammalian cells. By deep sequencing RNA samples from the lungs of ferrets infected with influenza viruses, we show that mvR-NAs are generated during infection in vivo. We propose that mvRNAs act as the main agonists of RIG-I during influenza virus infection.
their genome segments during infection by replicating them in the context of RNPs 11 . This led to the proposal that an aberrant RNA replication product might be binding to RIG-I and triggering IFN expression 12 . The influenza virus polymerase is known to generate defective interfering RNAs (DI RNAs), which are ≥ 178-nucleotide (nt) long subgenomic RNAs generated during high multiplicity infections 13 , and small vRNAs (svRNAs), which are 22-27-nt long and correspond to the 5′ end of vRNA segments. However, svR-NAs have been shown not to be involved in the induction of antiviral cellular defences 14 , and DI RNAs assemble into RNP structures (Fig. 1a) , as demonstrated for a 248-nt long DI RNA 15 , potentially precluding their interaction with RIG-I. Thus, it remains unclear what kind of influenza RNA species is recognized by RIG-I ( Fig. 1a ) and why different influenza virus strains trigger dramatically different levels of IFN expression 2, 3, 16 .
Engineered RNAs shorter than 149 nt but containing both the 5′ and 3′ termini of vRNAs can be transcribed and replicated by the viral polymerase in the absence of NP 17 , suggesting that they do not form canonical RNP structures. We call these influenza RNAs mini vRNAs (mvRNAs; Fig. 1a ). To investigate which class of influenza RNA is responsible for triggering IFN expression, we expressed a full-length segment 4 vRNA (1,775-nt long) or its truncated versions, a 245-nt long DI RNA and a 77-nt long mvRNA, in HEK293T cells together with viral polymerase and NP and measured the activation of the IFNB promoter ( Fig. 1b ). We found that the expression of mvRNAs induced significantly higher IFN expression than fulllength vRNA or DI RNA, comparable to the levels induced by the transfection of 2 μ g of poly(I:C), a known activator of IFN expression 18 . Similar results were obtained with segment 5 and segment 6 vRNAs and their truncated DI RNA and mvRNA versions (Fig. 1b) .
To determine the optimal mvRNA length that triggers IFNB promoter activation, we expressed 47-246-nt long RNAs derived from segment 5 together with viral polymerase and NP and measured the activity of the IFNB promoter. We found that the replication of 56-125-nt long mvRNAs resulted in significantly higher IFNB promoter activity than the replication of RNAs shorter than 56 nt or longer than 125 nt ( Fig. 1c and Supplementary Fig. 1a,b) .
To address whether these engineered mvRNAs triggered IFN expression via RIG-I, we co-expressed them with polymerase and NP in HEK293T RIG-I-knockout or control cells engineered to express luciferase in response to the activation of the IFNB
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Letters NATuRe MIcRoBIoloGy promoter. We found that 56-125-nt long mvRNAs induced only background levels of luciferase in RIG-I-knockout cells, even though the expression of RIG-I or the transfection of poly(I:C) resulted in significant activation of the IFNB promoter ( Fig. 1d and Supplementary Fig. 1c ). By contrast, significant levels of luciferase activity were detected in wild-type cells (Fig. 1d ). mvRNAs of 56-125 nt induced the strongest activation of the IFNB promoter, in agreement with the data above (Fig. 1c,d and Supplementary Fig. 1c,d) .
To address whether mvRNAs trigger the activation of IFN-β expression through binding to RIG-I, we immunoprecipitated Myc-RIG-I from cells expressing RNAs of 47-583 nt. We observed that mvRNAs of 56-125 nt were specifically enriched in RIG-I immunoprecipitates ( Fig. 1e and Supplementary Fig. 1e ). No mvRNAs were detected in the Myc-tagged epidermal growth factor (EGF)-negative control immunoprecipitates (Fig. 1e ). To test whether mvRNAs also activate RIG-I, we incubated purified Myc-RIG-I with an in vitrotranscribed 76-nt mvRNA and measured 32 P i release. We found that a triphosphorylated 76-nt mvRNA induced higher levels of ATPase activity than a dephosphorylated 76-nt mvRNA, whereas no ATPase activity was observed when we incubated a RIG-I mutant with the triphosphorylated 76-nt mvRNA ( Supplementary Fig. 1f,g) . Overall, these results demonstrate that mvRNAs longer than 47 nt and shorter than 125 nt are bound by RIG-I, which results in RIG-I activation and the induction of IFN-β expression. This is in agreement with findings that reconstitution of full-length influenza virus vRNPs leads to only low levels of IFN expression unless the cells are pre-treated with IFN 19 and the hypothesis that aberrant replication products trigger the IFN induction cascade 12 .
We next asked whether mvRNAs are made during influenza virus infection. We infected HEK293T cells with influenza A/ WSN/33 (H1N1) (abbreviated as WSN) and analysed influenza RNAs by reverse transcription and PCR (RT-PCR) of segment 1, RT-PCR of all segments using universal primers or deep sequencing of the total small RNA fraction (that is, RNAs 17-200 nt in length) ( Supplementary Fig. 2a,b ). We found only very low levels of mvRNAs and, consistently, observed no significant IFN expression ( Fig. 2a,b ). We hypothesized that mvRNAs are only generated as a consequence of dysregulated vRNA replication. To test this, we overexpressed influenza RNA polymerase prior to infection to generate an imbalance between polymerase and NP levels, which is known to induce innate immune signalling 20 . Under this condition, we found significantly higher levels of mvRNAs and IFN expression, whereas simultaneous overexpression of NP and polymerase reduced mvRNA and IFN production ( Fig. 2a ). We verified the identity of mvRNAs using gel isolation and Sanger sequencing ( Supplementary Fig. 2c ), as well as deep sequencing (Fig. 2b ). We found that the majority of mvRNAs were derived from the PB1-, haemagglutinin-, NP-and neuraminidase-encoding vRNA segments ( Fig. 2c ) and that mvRNAs had a size distribution with a peak around 55-64 nt ( Fig. 2d and Supplementary Fig. 2d ). 
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In addition to mvRNAs, we also identified mini complementary RNAs (mcRNAs). Analysis of mvRNA sequences suggests that mvRNAs are generated via an intramolecular copy-choice mechanism that tolerates 3′ mismatches or skipped bases ( Fig. 2e,f) . The generation of mvR-NAs can be explained by the separation of the template and nascent product RNAs by backtracking 21 , followed by template translocation until base pairing between the template and nascent product RNAs is re-established ( Fig. 2f,g) . This process may be induced by an imbalance between viral polymerase and NP levels ( Fig. 2a and Supplementary Fig. 3a ).
In humans, infection with the 1918 H1N1 pandemic virus or H5N1 highly pathogenic avian influenza viruses (HPAIVs) leads to strong innate immune activation 2, 3, 16 . To address whether mvRNAs could contribute to this phenomenon, we investigated the replication of a 246-nt RNA by the polymerase of these viruses. We found that the polymerases of the highly virulent A/Brevig Mission/1/18 (H1N1) (abbreviated as BM18) pandemic virus and the A/duck/ and steady-state vRNA and mvRNA levels (top gel) in WSN infections following overexpression of viral polymerase or viral polymerase and NP. mvRNAs were also amplified with universal primers containing adapters for sequencing (mvRNAs + adapt) and analysed by PAGE (second gel). NP, PB1 and tubulin expression was analysed by western blot (bottom three gels). P values were determined using ANOVA compared to lane 2. b, Quantitation of mvRNAs using deep sequencing, expressed as RPM. The P value was determined using a two-sided, unpaired t-test. c, mvRNA distribution per genome segment. HA, haemagglutinin; NA, neuraminidase; M, matrix; NS, non-structural. d, Size distribution of mvRNAs. e, mvRNA distribution per type of intramolecular copy-choice mechanism. f, An example of mvRNA formation through an intramolecular copy-choice mechanism involving a 3′ mismatch. The copied template RNA is shown in black upper-case letters and the skipped template is shown in grey lower-case letters. The product RNA generated before the intramolecular copy choice is coloured orange, the product RNA involved in re-annealing with the template RNA is coloured blue, and the RNA produced after the copy choice is coloured red. g, Model of mvRNA formation by the polymerase with the polymerase core in blue, the PB2 cap-binding domain (PB2 cap) and PB2 627 domain (PB2 627) in pink, and the PA endonuclease domain (PA endo) in green. The copied template RNA is depicted as a black line, the skipped template as a partially dotted grey line, and the product RNA as orange, blue and red lines, corresponding to the colour scheme in f. PL, priming loop. All graphs show the mean and standard deviation of data from two (b-d) or three (a,e) biologically independent experiments. Model in g adapted from ref. 6 , Springer Nature Ltd. 
Fig. 3 | the PB2 polymerase subunit of highly virulent influenza A viruses promotes mvRNA synthesis. a,
Analysis of mvRNA levels using primer extension (top gel) or RT-PCR (second gel) during the replication of a segment 5-based 246-nt RNA template by the WSN, BM18, NT60 and FJ02 polymerases, and IFNB promoter activity induced by the transfection of total RNA isolated from these cells into reporter HEK293T cells expressing luciferase. NP and PB1 expression was assessed by western blot (bottom two gels). n = 3 biologically independent experiments. P values were determined using ANOVA with adjustments for multiple corrections compared to WSN. b, The location of PB2 amino acid residues 9, 64 and 81 in the bat influenza A virus polymerase structure (Protein Data Bank ID: 4WSB). c, Analysis of the effect of PB2 mutations on mvRNA formation using RT-PCR (top gel) and IFNB promoter activity induced after transfection of total RNA isolated from these cells into luciferase reporter HEK293T cells. PB2, NP and tubulin expression was analysed by western blot (bottom three gels). P values were determined using ANOVA with adjustments for multiple corrections compared to WSN. n = 4 biologically independent experiments for all WSN mutants in the top graph. n = 3 biologically independent experiments for BM18 in the top graph and all samples in the bottom graph. d, IFNB promoter activity as a function of a PB2 mutation and mvRNA formation. Each data point was generated using the biologically independent experiments presented in panel c. P values were determined using linear regression. All graphs show the mean and standard deviation.
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Fujian/01/02 (H5N1) (abbreviated as FJ02) HPAIV generated higher levels of mvRNAs than the polymerases of WSN and A/Northern Territory/60/68 (H3N2) (abbreviated as NT60) viruses, even in the presence of high NP concentrations ( Fig. 3a) . No mvRNAs were observed in a control with an inactive WSN polymerase that had two point mutations in the polymerase active site (PB1a). We confirmed that the mvRNAs produced by the BM18 polymerase were similar to the WSN mvRNAs ( Supplementary Fig. 3b ). Isolation of total RNA from cells expressing polymerase of the BM18 or FJ02 virus and its subsequent transfection into HEK293T cells resulted in significantly higher IFNB promoter activity than when RNA from cells expressing WSN, NT60 or active-site mutant WSN PB1a polymerase was transfected (Fig. 3a) .
The identification of mismatches during the generation of mvRNAs (see Fig. 2e ) suggests that mvRNA production might be dependent on polymerase fidelity. To investigate this further, we introduced a V43I mutation, which has been shown to confer high fidelity on an H5N1 influenza virus polymerase 22 , into the PB1 subunit of the BM18 polymerase (BM18 hf ). We found that mvRNA levels were significantly reduced in the presence of BM18 hf , with a corresponding reduction in IFNB promoter activity ( Fig. 3a ). Taken together, the observations in Figs. 2a and 3 and Supplementary Fig. 3a suggest that dysregulation of vRNA replication, for example, by limiting NP availability, and replication by HPAIV polymerases in mammalian cells, generates mvRNAs by employing an error-prone copy-choice mechanism, such as that proposed for recombination in positive-strand RNA viruses 23 .
We next asked whether a particular BM18 polymerase subunit is the determinant of mvRNA production and replaced individual polymerase subunits of the BM18 polymerase with subunits of the WSN polymerase in the 246-nt RNA replication assay. We found that the replacement of the BM18 PB2 subunit with the WSN PB2 subunit eliminated the generation of mvRNAs ( Supplementary  Fig. 4a ). Interestingly, the BM18 influenza PB2 subunit has been linked to the enhancement of both the kinetics and the magnitude of the host response to viral infection, leading to the induction of strong inflammatory responses in the lungs of infected mice 24 . To identify the PB2 amino acids that are involved in mvRNA formation, we aligned the BM18, WSN, NT60 and FJ02 PB2 sequences and found four amino acids that distinguish the BM18 and FJ02 polymerases from the WSN and NT60 polymerases: 9 (D→ N), 64 (M→ T), 81 (T→ M) and 661 (A→ T) ( Supplementary Fig. 4a ). Each of these amino acids has been implicated in avian to mammalian host adaptation 25 and, interestingly, all three aminoterminal PB2-adaptive amino acids map to the template exit channel of the RNA polymerase 6 (Fig. 3b ). We generated single mutations-N9D, T64M and M81T-and double mutations-N9D + T64M and N9D + M81T-in the PB2 subunit of the WSN polymerase and found that the mutants N9D and M81T and the double mutants N9D + T64M and N9D + M81T significantly increased mvRNA formation ( Fig. 3c ) and IFNB promoter activity ( Fig. 3c,d) . However, the levels of mvRNAs generated by these mutants did not reach the levels generated by the BM18 polymerase, indicating that further amino acids contribute to mvRNA production. In line with our observations, WSN viruses that contain a PB2 N9D substitution or other PB2 mutations near the template exit channel have been reported to induce higher IFN-β expression than the wild-type WSN virus 26, 27 .
To address whether mvRNAs form during infection of mammalian cells, we infected A549 cells with the WSN virus, the highly pathogenic avian strain A/Vietnam/1203/04 (H5N1) (abbreviated as VN04) and the VN04 virus with the PB1 V43I high-fidelity mutation (abbreviated as VN04 hf ). Infections with the VN04 virus resulted in high levels of mvRNAs, whereas WSN virus infections produced only very low levels (Fig. 4a ). Infections with the VN04 hf virus resulted in significantly reduced mvRNA levels compared to the wild-type VN04 virus. These results demonstrate that mvRNAs are formed during influenza virus infection of lung epithelial cells and that polymerase fidelity is an important determinant of mvRNA formation (Fig. 4a ).
To investigate whether there is a link between mvRNA production and virus-induced innate immune responses, we performed RNA sequencing of cells infected with VN04 and VN04 hf viruses and examined which genes were differentially expressed in response to mvRNA generation. Despite significantly different mvRNA levels produced by the VN04 and VN04 hf viruses, viral mRNA levels were similar (Supplementary Data 1), in agreement with previous findings that the V43I mutation has only a marginal effect on virus replication 22 . Gene Ontology (GO) analysis ( Fig. 4b) showed that basic cellular functions were significantly compromised in VN04 infection relative to VN04 hf infection, consistent with a greater level of cell death, which is known to exacerbate inflammation 28 . In addition, we observed that genes associated with innate immune responses showed a significant increase in expression in response to higher mvRNA levels ( Fig. 4b ). Overall, these observations are indicative of a link between erroneous polymerase activity, mvRNA synthesis and innate immune activation and the induction of cell death. Furthermore, as the VN04 virus exhibited a tenfold higher lethality than the VN04 hf virus in mice 22 , our data also indicate a link between mvRNA levels and virulence.
To address whether mvRNAs are produced in infection of animal models, we analysed RNA samples from ferret lungs 1 and 3 days after infection with the highly pathogenic avian A/Indonesia/5/2005 (H5N1) (abbreviated as IN05), the 2009 swine-origin pandemic A/ Netherlands/602/2009 (H1N1) (abbreviated as NL09) or the BM18 pandemic virus 29, 30 . mvRNAs were present in all infected lung samples 1 day after infection, with mvRNA levels particularly high in the BM18-infected ferret lungs ( Fig. 4c and Supplementary Fig. 5 ). GO analysis on the ferret lung samples taken 1 and 3 days postinfection showed an upregulation of apoptosis and innate immune responses as a function of the mvRNA level, independently of viral titre or the day post-infection ( Fig. 4d ).
In summary, we identify mvRNAs, a class of influenza virus RNAs, that act as the main agonists of the pathogen recognition receptor RIG-I during influenza virus infection ( Fig. 4e ). mvR-NAs are produced as a result of aberrant replication of the vRNA genome by the influenza RNA polymerase. Polymerase fidelity and host-specific amino acids are determinants of the ability of the viral polymerase to produce mvRNAs, which are distinct from DI RNAs and full-length vRNA segments in that they can be efficiently replicated in the absence of NP and do not form canonical RNPs 17 . These features of mvRNAs are probably critical for their preferential recognition by RIG-I over DI RNAs and full-length RNA segments. We further demonstrate that mvRNA production is linked to increased cytokine expression and cell death. Thus, our observations strongly suggest that mvRNAs are a contributing factor to influenza virus virulence. We speculate that the production of high levels of mvR-NAs by the polymerases of the 1918 pandemic and the highly pathogenic avian influenza viruses and the resulting increased innate immune activation contribute to the cytokine storm phenomenon underlying the high virulence of these viral strains. The effects of mvRNAs are probably modulated by viral factors, such as the immunomodulatory NS1 and PB1-F2 proteins 12 (Fig. 4e ). Further studies are required to assess the mvRNA levels generated by various influenza virus strains, including seasonal strains, and their effect on virulence. Plasmids. Plasmids expressing the three polymerase subunits and NP of influenza WSN (H1N1) 31 , NT60 (H3N2) 32 , FJ02 (H5N1) 32 (all pcDNA3 based) and BM18 (H1N1) 33 (pCAGGS based) have been described. A PB2 E627K mutation was introduced into the FJ02 (H5N1) PB2 subunit to enable the FJ02 polymerase to efficiently replicate vRNA in mammalian cells. Plasmids expressing mutant PB1a (D445A/D446A) 34 and mutant PB2 (N9D) 26 of the influenza WSN (H1N1) virus have been described previously. Full-length or internally truncated vRNAs were expressed from plasmids under the control of the cellular RNA polymerase I promoter 35 . The luciferase reporter plasmid under the control of the IFNB promoter (pIFΔ (-116)lucter), the β -galactosidase (β -gal) reporter plasmid (pJatLacZ) under the control of a constitutive promoter, pcDNA-Myc-RIG-I expressing Myc-tagged RIG-I and pcDNA-Myc-proEGF have been described previously 36, 37 . To construct the plasmids expressing mutant PB1, PB2 proteins and Myc-RIG-I (Myc-RIG-I mut; which contains the mutations K851A, K858A and K861A), the plasmids expressing wild-type proteins were subjected to site-directed mutagenesis using the primers listed in Supplementary Table 1 .
Methods
Ethics
Cells and antibodies.
Human embryonic kidney HEK293T cells were originally sourced from the American Type Culture Collection, stored in the Dunn School cell bank at the University of Oxford, UK, and mycoplasma tested but not authenticated before our experiments. A549 cells were originally sourced from the American Type Culture Collection and cultured at the University of Hong Kong, China. The cells were cultured in DMEM (Sigma-Aldrich) and 10% FCS. Western blots were performed using the NP antibody GTX125989 (GeneTex), the Myc antibodies GTX115046 (GeneTex) and M4439 (Sigma), the RIG-I antibody GTX85488 (GeneTex) and the PB2 antibody GTX125926 (GeneTex). Wild-type and RIG-I-knockout HEK293T cells expressing luciferase in response to the activation of the IFNB promoter were described previously 38 .
Statistical testing. In all figures, error bars indicate the standard deviation with sample sizes as indicated in the figures or figure legends. Evaluation of the statistical significance between group means was performed across all experiments according to the following criteria: (1) in the case in which a comparison of a single variable was made between only two groups, an unpaired t-test was used;
(2) in the case of comparisons between three of more groups of measurements derived from a single independent variable (for example IFN-β induction as a function of RNA length), one-way analysis of variance (ANOVA) was used and the P values were corrected for multiple comparisons using either the Dunnett's test (when a single group was taken as a reference or control to which all other groups were compared) or the Bonferroni method (when specific pairs of groups were compared to one another); (3) in the case of comparisons between three of more groups of measurements derived from two independent variables (for example, IFN-β induction as a function of RNA length and RIG-I expression), two-way ANOVA was used and the P values were corrected for multiple testing using the Bonferroni method; (4) in the case of comparisons between three of more groups of log-distributed data (for example, viral titres), the measured values were first 
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NATuRe MIcRoBIoloGy log 10 transformed and then compared using one-way ANOVA, with the P values corrected for multiple comparisons by controlling the false discovery rate to be < 0.05 using the two-stage step-up method of Benjamini, Kreiger and Yekutieli. For the evaluation of the statistical significance of the relationship between two measured values (for example, the fold increase in IFN-β induction versus mvRNA level), linear regression analysis was used, with the P value indicating the probability of the null hypothesis (no linear relationship) and the goodness of fit reported as r 2 . Statistical testing related to differential gene expression analysis is detailed below and was performed in R; all other statistical tests were performed using GraphPad Prism.
RNP reconstitution assays and quantitative RNA analysis. RNP reconstitution assays were carried out in 24-well plates as described previously 34, 39 . Briefly, 0.25 μ g of the plasmids pcDNA3-NP, pcDNA3-PB2, pcDNA3-PB1, pcDNA3-PA and a pPOLI plasmid encoding full-length or truncated vRNA templates (for the list of vRNA templates used, see Supplementary Table 2 ) were transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Twenty-four hours post-transfection, RNA was extracted using TRI Reagent (Sigma-Aldrich) and dissolved in RNase free water. For quantitative primer extensions, reverse transcription was carried out using SuperScript III reverse transcriptase (Thermo Fisher Scientific) with 32 P-labelled oligonucleotides complementary to vRNA-derived RNA species and ribosomal 5S rRNA (for primers, see Supplementary Table 3 ). cDNA synthesis was stopped with 10 μ l loading dye (90% formamide, 10 mM EDTA, xylene cyanole and bromophenol blue) and 32 P-labelled cDNAs generated with primer NP were resolved by 12% denaturing PAGE (19:1 acrylamide/bisacrylamide, 1× TBE buffer and 7 M urea). 32 P-labelled cDNAs generated with primer NP-2 were resolved by 20% denaturing PAGE. The radiolabelled signals were imaged using phosphorimaging on a FLA-5000 scanner (Fuji) and analysed using AIDA (RayTek) and Prism 7 (GraphPad). In all experiments, the apparent RNA levels were background corrected using the PB1a signal and normalized to the 5S rRNA control. Statistical analysis of data from at least three independent experiments was carried out using ANOVA.
RNP reconstitution assays and qualitative RNA analysis.
For segment-specific qualitative RNA analysis by RT-PCR, RNA was treated with DNase (Promega) for 10 min according to the manufacturer's instructions and reverse transcribed using SuperScript III and the PB2 primers listed in Supplementary Table 3 . cDNA was amplified using Q5 polymerase (NEB) and the primers listed in Supplementary  Table 3 . PCR products were analysed on 1.5% agarose gels in 0.5× TAE buffer. For qualitative RT-PCR using universal primers, DNase-treated RNA was reverse transcribed using the Lv3aa and Lv3ga primers listed in Supplementary Table 3 and Superscript III at 37 °C for 30 min. Second strand synthesis was performed with primer Lv5 and Q5 polymerase (NEB) at 47 °C for 10 min, followed by a further extension at 72 °C for 3 min. The primer excess in the reactions was removed by incubating the second strand reaction with 1 U exonuclease VII (NEB) at 37 °C for 1 h. Following inactivation of the exonuclease at 95 °C for 10 min, the DNA was amplified using Q5 polymerase and the primers P5 and i7 for 25 cycles. PCR products were analysed by 6% PAGE.
Luciferase-based IFN expression assays. For luciferase assays, RNP reconstitutions were performed in wild-type HEK293T cells or in HEK293T cells engineered to express luciferase from the IFNB promoter. RNP reconstitutions were performed in a 24-well format by transfecting 0.25 μ g of the plasmids pcDNA3-NP, pcDNA3-PB2, pcDNA3-PB1, pcDNA3-PA and a pPOLI plasmid encoding full-length or truncated vRNA templates using Lipofectamine 2000 (Invitrogen). For RNP reconstitutions in wild-type HEK293T cells, 100 ng pIFΔ (− 116)lucter and pJatLacZ were co-transfected with the polymerase-expressing plasmids. Twenty-four hours post-transfection, cells were harvested in PBS and resuspended in Reporter Lysis buffer (Promega). Luciferase activity was measured using a Luciferase Assay System (Promega) and a GloMax (Promega), and normalized using the β -gal signal measured using ortho-nitrophenyl-β -galactoside and a GloMax. The background was subtracted using signals obtained from cells transfected with an empty pcDNA3 plasmid. Luciferase levels were corrected for vRNA levels obtained with primer extensions and a 32 P-labelled NP-2 primer (Supplementary Table 3 ). For total RNA transfections, 100 ng total RNA was transfected with 100 ng pIFΔ (− 116)lucter and pJatLacZ using Lipofectamine 2000. Analysis of the luciferase expression was performed as described above. Statistical analysis was carried out using ANOVA.
Immunoprecipitations. For Myc-RIG-I immunoprecipitations, 10-cm dishes with HEK293T cells were transfected with 3 μ g pcDNA3-NP, pcDNA3-PB2, pcDNA3-PB1, pcDNA3-PA, pcDNA-Myc-RIG-I or pcDNA-Myc-EGF and a pPOLI plasmid encoding either a full-length or truncated vRNA template using Lipofectamine 2000. Twenty-four hours post-transfection, the cells were harvested in cold PBS and lysed in 600 μ l Tris lysis buffer (50 mM Tris-HCl, pH 8.0, 5% glycerol, 0.5% Igepal, 200 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol and 1× EDTA-free protease inhibitor (Roche)) on ice for 1 h. The lysates were cleared at 10,000g for 5 min. Anti-Myc antibody (6 μ g; Sigma-Aldrich) was added to 0.5 ml cleared lysate and mixed at 4 °C for 1.5 h. The lysate-antibody mix was bound to Dynabeads (Novex) at 4 °C for 1.5 h, washed 3 times with IgG wash buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Igepal, 1 mM phenylmethyl sulfonyl fluoride and 1 mM EDTA) and finally analysed for bound RNA and protein. Statistical analysis of data from three independent experiments was carried out using ANOVA.
ATPase assay. For wild-type and mutant Myc-RIG-I purification, HEK293T cells were transfected with 5 μ g pcDNA-Myc-RIG-I or pcRNA-Myc-RIG-I mut using Lipofectamine 2000. Twenty-four hours post-transfection, the cells were harvested in cold PBS and lysed in lysis buffer (50 mM HEPES, pH 8.0, 5% glycerol, 0.5% Igepal, 200 mM NaCl, 2 mM MgCl 2, 10 mM CaCl 2 , 1 mM dithiothreitol, 1 U ml -1 Micrococcal Nuclease (Thermo Scientific) and 1× EDTA-free protease inhibitor) on ice for 1 h. Anti-Myc antibody (3 μ g) was next added per 0.5 ml cleared lysate and mixed at 4 °C for 1.5 h. The lystate-antibody mix was bound to Protein G Mag Sepharose Xtra beads (GE Healthcare) at 4 °C for 1.5 h, washed 6 times with 20-column volumes of RIG-I wash buffer (50 mM HEPES, pH 8.0, 200 mM NaCl, 0.1% Igepal, 5% glycerol, 1 mM phenylmethyl sulfonyl fluoride and 2 mM MgCl 2 ) at 4 °C for 10 min, and finally, Myc-RIG-I was eluted from beads in 1-column volume wash buffer containing 0.5 mg ml -1 Myc peptide (Pierce) for 15 min at 4 °C. Activity assays were performed in 50 mM HEPES, pH 8.0, 150 mM NaCl, 2 mM MgCl 2 , 5 mM dithiothreitol and 0.1 μ M [γ -32 P]ATP. [γ -32 P]ATP and 32 P i were resolved using PEI-cellulose TLC plates (Sigma-Aldrich) in 0.4 M KH 2 PO 4 , pH 3.4.
Cell and animal infections. HEK293T cells were infected with influenza WSN (H1N1) virus, free of DI RNAs, at a multiplicity of infection of 5. RNA was extracted 5 h post-infection and analysed using deep sequencing or qualitative RT-PCR. Six wells containing A549 cells were infected with WSN (H1N1), VN04 (H5N1) or VN04 (H5N1) with the V43I mutation using a multiplicity of infection of 5. RNA was extracted 8 h post-infection and analysed using deep sequencing or qualitative RT-PCR. Ferret (Mustela putorius furo) lung tissue was obtained from male ferrets infected with IN05 (H5N1) or NL09 (H1N1) viruses 29 or from female ferrets infected with A/Brevig Mission/1/1918 (H1N1) 30 . Ferrets were randomly assigned to groups of four before inoculation. A single ferret (lung titre = 7.6 × 10 1 log 10 TCID 50 (tissue culture infectious dose) per gram) was excluded from analysis on the basis of its apparent lack of infection. Ferret RNA was isolated from the lung tissue samples using TRIzol (Invitrogen) and analysed using qualitative RT-PCRs and next-generation mvRNA sequencing with universal primers and quantitative mRNA sequencing.
Sequence alignment and structural modelling. PB2 amino acid sequences from influenza A viruses WSN (H1N1), BM18 (H1N1), NT60 (H3N2) and FJ02 (H5N1) were aligned using Muscle 3.0 and visualized using ESPript 40 . The bat influenza A virus polymerase structure (Protein Data Bank ID: 4WSB) was visualized in Pymol 1.6.
Next-generation sequencing of mvRNAs using adapters. Total cell RNA from transfected or infected cells was isolated using Tri Reagent (Sigma) or TRIzol (Invitrogen) according to the manufacturer's instructions and fractionated into small (17-200 nt) and large (> 200 nt) RNA fractions using an RNA Clean and Concentrator kit (Zymo Research). Next, the small RNA fraction was denatured at 70 °C for 2 min and subsequently treated with 2 U XRN-1 in NEB buffer 2 at 37 °C for 15 min to deplete microRNAs. Next, XRN-1 was inactivated by adding 10 mM EDTA and incubating the reaction at 70 °C for 10 min. Viral triphosphorylated RNAs were converted to monophosphorylated RNAs by adding 5 U RNA 5′ pyrophosphohydrolase and 10 mM MgCl 2 and incubating the reactions at 37 °C for 15 min. RNA was purified using an RNA Clean and Concentrator kit, and libraries for deep sequencing were prepared using the NEBNext Small RNA Library Prep Kit according to the manufacturer's instructions. To ensure accurate quantitation after PCR amplification, the concentration of each library was measured by quantitative PCR on a StepOnePlus instrument (ABI), and the number of PCR cycles used to subsequently amplify the remaining library material was calibrated to ensure that the PCR was in the early stage of exponential amplification and to not overcycle the PCR reactions. Amplified sequencing libraries were purified on a 6% Novex TBE PAGE according to the manufacturer's instructions to remove primer dimers. Paired-end sequencing (2 × 75 bp) on an Illumina HiSeq 4000 was carried out by the Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics (Oxford, UK). It is important to note that the existence of mvRNAs has probably been overlooked until now because: (1) RNA isolation protocols vary in their capacity to recover small RNAs, (2) RT-PCR products from mvRNAs form a diffuse fast-migrating band on standard agarose gels that may be mistaken for primer dimers, (3) conventional RNA deep-sequencing protocols discard short library fragments, and (4) standard ligation-based deep-sequencing protocols do not detect viral transcripts with a 5ʹ -triphosphate group.
Next-generation sequencing of mvRNAs using universal primers. To spike vRNA for quantitative sequencing, 0.2 μ l of 100 pM spike RNA (Supplementary Table 2 ) was added to 40 ng of the small RNA fraction (see above). The RNA mixture was next converted into cDNA using the primers Lv3aa, Lv3ga and Lc3 and Superscript III (Invitrogen) at 37 °C for 30 min. Second strand synthesis was performed using Q5 polymerase (NEB) and the primers Lv5, Lc3a and Lc3g at Letters NATuRe MIcRoBIoloGy 47 °C for 10 min, followed by a further extension at 72 °C for 3 min. The excess of barcoded primers was removed by incubating the second strand reaction with 1 U exonuclease VII (NEB) at 37 °C for 1 h. The exonuclease was inactivated at 95 °C for 10 min. Next, the DNA was amplified using Q5 polymerase, primer P5 and i7 index primers (Lexogen) and subsequently sequenced on a NextSeq 500 sequencer (Illumina).
Preparation of reference genome files for deep sequencing of mvRNAs.
Before mapping, a reference genome file was prepared from relevant viral reference sequences in Genbank (see above). For the analysis of sequencing libraries prepared using universal influenza virus primers, the 5′ and 3′ viral promoter sequences of each segment were modified to match the degenerate universal primer sequences used in sample preparation (see Supplementary Table 3 ), and the sequences of the spiked-in mvRNA quantitation standards (see Supplementary  Table 2 ) were appended to the reference genome. For WSN, VN04 and VN04 hf viruses, deep-sequencing data of mRNA generated in the A549 cell infections (above) were exploited to generate updated reference genome files: the mpileup and consensus commands in the bcftools software package 41 were used following mapping of non-host mRNA reads to the relevant viral reference genome using the STAR aligner 42 .
Data processing pipeline for deep sequencing of mvRNAs using universal influenza virus primers. Raw sequencing reads were first trimmed to remove sequencing adaptor sequences and reads with quality scores less than 20 using the cutadapt software package 43 , and the 8-nt unique molecular identifier (UMI) at the start of each read were removed from the sequence and appended to the read ID line of the FASTQ file using the extract command from the umi_tools software package 44 . Sequencing reads were then mapped end-to-end to the appropriate viral reference genome using the STAR aligner 42 , permitting sequencing reads to have long internal deletions (that is, an mvRNA, interpreted as splicing by STAR) with at least 16 nt anchored on either side of the deletion (--outSJfilterOverhangMin 16 16 16 16) . The default settings of STAR were modified so that no alignment scoring penalty was given for an internal deletion and no preference was given to internal deletions that overlapped particular sequence motifs (--scoreGapNoncan 0 --scoreGapGCAG 0 --scoreGapATAC 0), and to ensure accurate quantitation; only the top-scoring alignment was included in the outputted BAM file (--outSAMmultNmax 1), which was sorted and indexed using SAMtools 45 . An aligned read was counted as an mvRNAs if it was anchored to the viral reference genome at the 5′ end in the vRNA sense and contained an internal deletion (called a splice junction by STAR), and the total numbers of mvRNAs and spiked-in quantitation standards were tallied using the idxstats command of SAMtools. mvRNA levels relative to the quantitation were then reported as the number of reads per million mapped (RPM) quantitation standard. To validate the quantitative PCR protocol used to prevent overcycling of sequencing libraries, the quantitation was then repeated following the removal of PCR duplicates, exploiting the UMI appended to each read, using the umi_tools dedup command, and counting the various mvRNA species as unique using the --spliced-is-unique option. The identities of the individual mvRNAs were then extracted from the SJ.out.tab file generated by STAR.
Data processing pipeline for deep sequencing of mvRNAs using adapter ligation. Raw sequencing reads were first trimmed using the cutadapt software package 43 to remove RNA adapters, sequencing adapters and reads with quality scores less than 20. As adapter ligation captures both host-derived and virusderived small RNA species, reads were first mapped end-to-end to the DASHR database of human small RNAs 46 using the STAR aligner 42 , with spliced alignments disabled (--alignIntronMax 1). Non-human reads were outputted using the --outReadsUnmapped Fastx option, were then mapped to the appropriate viral reference genome to find mvRNAs as described above and quantitated relative to the total number of viral reads (RPM viral) or host reads (RPM host).
Quantitative mRNA sequencing and differential gene expression analysis.
Libraries for gene expression analysis were prepared using a QuantSeq 3′ mRNA-Seq Library Prep Kit FWD for Illumina (Lexogen) according to the manufacturer's instructions and sequenced on a NextSeq 500 sequencer. mRNA reads were aligned to the reference genome (CRCh38, GRCm38 or MusPutFur1.0) using the STAR read aligner 42 , exploiting the built-in trimming functions to remove the first 12 bases that correspond to the Lexogen random primer (--clip5pNbases 12) and any contaminating poly(A) tails in the sequencing reads (--clip3pAdapterSeq AAAAAAAAAAAAAAAAAA), as well as requiring a minimum match to the reference genome of 40 bp (--outFilterMatchNmin 40). Gene counts were generated using reference genome annotations (Gencode v26 for CRCh38 and Ensembl 90 for MusPutFur1.0) using the STAR command --quantMode GeneCounts. Differential gene expression analysis was then carried out using the DEseq2 package in R 47 to identify genes that were upregulated or downregulated as a function of mvRNA levels, independently of viral load or titre. Specifically, the likelihood ratio test was used to compare a full model (in which gene expression varies as a function of both viral load or titre and mvRNA levels) to a reduced model (in which changes in gene expression are fully explained by viral load or titre alone) using analysis of deviance to generate a P value for the log fold change of each gene, which were adjusted for multiple testing by controlling the false discovery rate using independent hypothesis testing 48 and reported as q values. mvRNA levels were determined by deep sequencing using universal influenza virus primers, as detailed above. Viral load or titre was determined by segment 6 quantitative RT-PCR or by using previously published values 29, 30 . Subsequent enrichment analysis of GO terms that are specifically affected by mvRNA levels was carried out using parametric analysis of gene set enrichment 49 via the GAGE package in R, with data from the above genome annotations, accessed via the biomaRt package 50 . The significance of enrichment for GO terms was calculated using a one-sample z-test 49 in GAGE, and P values were adjusted for multiple testing using the Benjamini-Hochberg method and were reported as q values.
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